A Phase I, Three-Arm Safety, Tolerability, and Pharmacokinetic Interaction Study of PA-824, an Investigational Nitroimidazole for the Treatment of Tuberculosis, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

Trial Profile

A Phase I, Three-Arm Safety, Tolerability, and Pharmacokinetic Interaction Study of PA-824, an Investigational Nitroimidazole for the Treatment of Tuberculosis, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Pretomanid (Primary) ; Efavirenz; Lopinavir/ritonavir; Rifampicin
  • Indications HIV infections; Tuberculosis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 06 May 2013 Planned End Date (Jun 2013) added as reported by ClinicalTrials.gov.
    • 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Sep 2012 Actual initiation date (Jun 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top